Here's the sub rosa reason Geron is confident and so am I
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
biopearl123
- Posts: 2591
- Joined: Fri Jul 20, 2018 5:13 pm
Here's the sub rosa reason Geron is confident and so am I
There is lots of good stuff out there for those who wish to see it. First off it is so very silly to hold Geron's feet to the fire with only three quarters of income (they are after all selling drug). A new drug that has an MOA so different from anything ever on the market before requires educating prescribers. If you look at the centers involved in the L/R MDS study you will see that most are from, well, not here. So the rest of the world has had way more experience with the drug then our own centers. I have talked about the conservative bent docs have in the interest of protecting their patients. Pioneer has the arrow in his back etc. Discussed previously. Acceptance and experience take time (and education). Heme/Onc guys are pros and will want to offer this drug to their patients. But the real deal is the MOA that spans and shares a uniformity with other hematologic malignancies. Namely targeting the CSC in a semi specific manner. It's true for MF, MDS and AML and maybe others. (Some mutations than others more sensitive of course). But a unifying approach has great appeal since many drugs attack narrow windows of mutation types. Also there seems to be some sense the minimal residual disease a major problem re recurrence may be particularly sensitive. So. MF: watch for the Rux/Imet comb data either at EHA or the rapid abstract at ASCO. The preliminary data looked very interesting. But here is where the confidence comes in. Dr. Bruedigam. She is a rising star and recently from QIMR to Monash University in Australia. She has been recognized as a first class researcher and won several awards. She outgrew Dr. Lanes' lab and has received significant grant support for her work in AML. Her seminal article in Nature speaks for itself as her Herculean efforts to define the effects of Imetelstat on ferroptosis in AML shine. So Geron knows about this. In a big way. Her abstract at ASH showed a reduction of 98% AML cells in mice with Ven/Aza Imet. Let me say that again circulating AML cells went from 99% to 1 % AND STAYED THERE. For how long you might ask? Long enough for the data not to be ready to be presented at the last meeting. What does that translate to? No mortality during the initial observation period. Near as I can tell that is about 6 months so far but don't know for sure. Mice with 99% AML die within days/weeks. I think this is what Geron knows and also why the Dr. B's abstract seems to be under wraps. It's the only one that was not posted on the Geron web site. It's also foundational for the TELOMERE study. If true (and I speculate on all counts), full speed ahead with the hiring and sales force that we are seeing and are bewildered by, that will not only be dealing with MDS but MF and some percentage of AML patients like FLT-3 subtypes that were examined in the preclinical study. We will hear more from Dr. B. She is modest but fierce. Not to mention super intelligent and she is on the trail of something important. This is all conjecture on my part as I see very dim dots to connect. Geron has been punished by the world of finance but will be rewarded by a grateful world of medicine. Time to take off the wraps. Good luck to all and Best wishes, bp
Re: Here's the sub rosa reason Geron is confident and so am I
Geron will never be considered a great equity investment even with MF as another indication, and even if terrific data supports that indication. Why do you ask?
1. J&J leaving us still negatively affects us to this day. Not many BPs want sloppy seconds, even if supportive data is great. Stock price means everything to an acquiring entity, and in all fairness, RYTELO shouldn’t be a cheap pick-up, but it will likely be a gas station big-gulp by some BP soon, and who’d argue?
2. Board members are wealthy, so F*CK retail. Geron isn’t the first publicly traded company to hold those beliefs. We also aren’t the first to vote “no” to their irresponsible pay raises and embarrassing salaries that don’t reflect a respectable stock price.
3. Blockbuster my *ss. Part of Geron’s problem is they’ve never been able to equate “blockbuster” to stock price. It’s been a lot of hot air and chest pounding since approval. Geron wasn’t prepared and still aren’t prepared to sell or market our great medicine.
4. “Looking for a partner” was on their website with the stupid rocking horse not very long ago. That ridiculous rocking horse was and is a metaphor for management’s ineptitude at selling their product and saddling us with whatever’s left—which is a broken down carousel of plastic horses @ $1.00 a ride.
1. J&J leaving us still negatively affects us to this day. Not many BPs want sloppy seconds, even if supportive data is great. Stock price means everything to an acquiring entity, and in all fairness, RYTELO shouldn’t be a cheap pick-up, but it will likely be a gas station big-gulp by some BP soon, and who’d argue?
2. Board members are wealthy, so F*CK retail. Geron isn’t the first publicly traded company to hold those beliefs. We also aren’t the first to vote “no” to their irresponsible pay raises and embarrassing salaries that don’t reflect a respectable stock price.
3. Blockbuster my *ss. Part of Geron’s problem is they’ve never been able to equate “blockbuster” to stock price. It’s been a lot of hot air and chest pounding since approval. Geron wasn’t prepared and still aren’t prepared to sell or market our great medicine.
4. “Looking for a partner” was on their website with the stupid rocking horse not very long ago. That ridiculous rocking horse was and is a metaphor for management’s ineptitude at selling their product and saddling us with whatever’s left—which is a broken down carousel of plastic horses @ $1.00 a ride.
-
stanleyock
- Posts: 38
- Joined: Thu Mar 17, 2016 6:59 am
Re: Here's the sub rosa reason Geron is confident and so am I
KT, excellent post - I share the same sentiment as you. Don’t ever dream and hope for any catalyst at all– not even with new CEO in the horizon or the gradual sales growth in the next few qtrs. as painted in the call or the eventual ‘positive readout’ from MF that never seem to see the light of days for the next 3 years and by then guess what remains of Gern’s stock given the constant assault at ease by those manipulating scumbags aided by a non-vigilant and silent leadership team and BOD. It would be reduced to ‘rubbles’ befitting a pink sheet company rather than an emerging pharma behemoth like regeneron that chip once made us believed. They should all be ashamed and taken to task for emboldening such illicit and unfair practices that erode trust and confidence in the investing community.
This is the intro to Geron Corporate Governance:-
The Board of Directors (the “Board”) of Geron Corporation (“Geron” or the “Company”) has adopted the following principles as the Company’s corporate governance guidelines (“Guidelines”) to assist the Board in its exercise of its responsibilities and to serve the interests of the Company and its stockholders. These Guidelines, along with the Company’s Certificate of Incorporation and Bylaws, the charters of the Board committees and other corporate governance documents, provide the framework for the governance of the Company and should be interpreted in light of the foregoing and in the context of all applicable laws. These Guidelines reflect the Board’s commitment to monitor the effectiveness of policy and decision making at both the Board and the management level, with the objective of enhancing stockholder value over the long term. As the operation of the Board is a dynamic process, with the aid of the Nominating and Corporate Governance Committee, the Board will review these Guidelines periodically and may make changes from time-to-time as the Board may deem appropriate and in the best interests of the Company and its stockholders or as required by applicable laws and regulations. These Guidelines are intended to serve as a flexible framework within which the Board may conduct its business and not as a set of legally binding obligations.
We have all walked the journey with Geron for decades. Aren’t we long term holders? And look at what the Gern’s stock value today? You call that serving the interests of its stockholders with the objective of enhancing its value?
Anil was employed in 2019 with big fat salary and compensation to build a commercial team in preparation for Imetelstat’s FDA approval and launch. He had been working on it for five years and at each earning calls we were led to believe they were all up and ready to go. But look at what happened when that approval finally came in Jun’24, he kaput soon after and chip had to scramble a non-commercial VP and Bir team-up to spearhead instead. That in itself is a red flag we retail did not see it coming as we trusted our 14 years veteran captain to steer the ship. But that too was not to be as we all known Chip also abandoned ship 9 months after and Bir steps in with a slew of desperate recruitment measure to shore up the commercial team as manifested in Gern’s current largest 38 positions to be filled.
This therefore begs a lot of questions as to what happen to the team that Anil built over the years – have they all gone rogue and depart with Anil? What about those huge compensation vested to Anil, Chip and the absconded gangs - are they still be entitled? Apparently we will never able to know all these and what mis-steps after another that led to the unthinkable state we are in – instead of celebrating the jewel in Geron's crown elevation to revenue earning commercial company, we are now left to lick the wound inflicted by an indifferent management and BOD to the blatant indiscriminate destruction of shareholders value.
BP, with all due respect and in all honesty, the science has to take a back seat. The grip by these fraudulent manipulators are not going anywhere by a long shot sans a buyout. We need to act and act decisively.
BP, please lead in yr command to all retail investors in this coming AGM to join forces in no uncertain terms in voting NO to all resolutions except the last one on other matters. For this last resolution I am inspired by activist investors like Icahn or Elliot in seeking board seats when things are not aligned with theirs. Am thinking more of you BP, given yr stature and respect by all of us here and Kmall will be a good representation of our voices in the board if I may say so. This is real and not in jest. That will make the board sit up and do something to address our immediate concern to stem the erosion of Geron’s intrinsic value and fulfil their fiduciary duties in protecting the interest of shareholders and enhancing its value.
Am a lone voice here in farway places . This is the moment, BP, I am looking up to you for yr leadership!
All the best!
StanleyRock, Singapore
This is the intro to Geron Corporate Governance:-
The Board of Directors (the “Board”) of Geron Corporation (“Geron” or the “Company”) has adopted the following principles as the Company’s corporate governance guidelines (“Guidelines”) to assist the Board in its exercise of its responsibilities and to serve the interests of the Company and its stockholders. These Guidelines, along with the Company’s Certificate of Incorporation and Bylaws, the charters of the Board committees and other corporate governance documents, provide the framework for the governance of the Company and should be interpreted in light of the foregoing and in the context of all applicable laws. These Guidelines reflect the Board’s commitment to monitor the effectiveness of policy and decision making at both the Board and the management level, with the objective of enhancing stockholder value over the long term. As the operation of the Board is a dynamic process, with the aid of the Nominating and Corporate Governance Committee, the Board will review these Guidelines periodically and may make changes from time-to-time as the Board may deem appropriate and in the best interests of the Company and its stockholders or as required by applicable laws and regulations. These Guidelines are intended to serve as a flexible framework within which the Board may conduct its business and not as a set of legally binding obligations.
We have all walked the journey with Geron for decades. Aren’t we long term holders? And look at what the Gern’s stock value today? You call that serving the interests of its stockholders with the objective of enhancing its value?
Anil was employed in 2019 with big fat salary and compensation to build a commercial team in preparation for Imetelstat’s FDA approval and launch. He had been working on it for five years and at each earning calls we were led to believe they were all up and ready to go. But look at what happened when that approval finally came in Jun’24, he kaput soon after and chip had to scramble a non-commercial VP and Bir team-up to spearhead instead. That in itself is a red flag we retail did not see it coming as we trusted our 14 years veteran captain to steer the ship. But that too was not to be as we all known Chip also abandoned ship 9 months after and Bir steps in with a slew of desperate recruitment measure to shore up the commercial team as manifested in Gern’s current largest 38 positions to be filled.
This therefore begs a lot of questions as to what happen to the team that Anil built over the years – have they all gone rogue and depart with Anil? What about those huge compensation vested to Anil, Chip and the absconded gangs - are they still be entitled? Apparently we will never able to know all these and what mis-steps after another that led to the unthinkable state we are in – instead of celebrating the jewel in Geron's crown elevation to revenue earning commercial company, we are now left to lick the wound inflicted by an indifferent management and BOD to the blatant indiscriminate destruction of shareholders value.
BP, with all due respect and in all honesty, the science has to take a back seat. The grip by these fraudulent manipulators are not going anywhere by a long shot sans a buyout. We need to act and act decisively.
BP, please lead in yr command to all retail investors in this coming AGM to join forces in no uncertain terms in voting NO to all resolutions except the last one on other matters. For this last resolution I am inspired by activist investors like Icahn or Elliot in seeking board seats when things are not aligned with theirs. Am thinking more of you BP, given yr stature and respect by all of us here and Kmall will be a good representation of our voices in the board if I may say so. This is real and not in jest. That will make the board sit up and do something to address our immediate concern to stem the erosion of Geron’s intrinsic value and fulfil their fiduciary duties in protecting the interest of shareholders and enhancing its value.
Am a lone voice here in farway places . This is the moment, BP, I am looking up to you for yr leadership!
All the best!
StanleyRock, Singapore
Re: Here's the sub rosa reason Geron is confident and so am I
It’s regrettable to see such frayed nerves. And obviously understandable. But I do personally don’t track with the reasoning. I’ll just make a few points from what I read here, and disclaimer IMO:
First about the shareholder meeting. This is the easy one… I have to point out to be mindful that all the measures put forward will pass. Institutions do own about 80% of the shares still. I understand sending a message, but staying rationale that all measures will pass.
Secondly, there certainly was a debacle w Anil and 5 years of preparing to be unprepared… however, the Rytelo launch is also certainly not all doom and gloom. I will point you to a post on StockTwits this morning about the competitor drug launch Revs… I’ll go and copy/paste it in another thread, but essentially it shows the slow uptake in the first year or so. The previous top Execs certainly messaged poorly, for lack of a curse word, but probably because Dr Scarlett was skilled at drug development but not really experienced with drug commercialization. Now the company has new execs, who are experienced with drug launch commercialization.
So I feel the angst but I don’t feel the storm the Bastille slash potential capitulation vibes … not saying it’s wrong to voice it and have those feelings, I’m just saying I’m not there. Rytelo works and will have uptake, in both the US and soon Europe. Losing patience is justified, but nonetheless patience continues to be warranted.
I’ll also point you to the video of Dr Santini, posted on YouTube yesterday… that was posted on StockTwits (StockTwits coming up money this morning) - longer life expectancy has not been proven out, which is frustrating obviously , and heartbreaking for patients… however Quality of Life is improving , transfusion independence is a real milestone … quick detour to say I wish my dad could have had TI for a short while in the last 3.5 years of his life… and QoL is huge. and the drug is being used in 2nd (by Santini) and ‘mostly 3rd line,,, so there may be potential life expectancy improvement.
Needless to say, this drug therapy is a winner.
I don’t join the line of thought that this is not proving out to be a valuable drug.
Third, and it’s a point of contention and I apologize for being vocal, and inappropriately vocal at times about this, but it’s just a point of fact that there is economic and, in the NIH, political turbulence right now, which as a further point of fact clouds the prospects for new and future drugs. The Biotech indices are down 20% in the past 6 months, and indie / small biotechs have all been pulverized. There has been few mergers / acquisitions of note, which is a marketplace which may have effected the companies plans. But I do think personally that this general market flux is more to blame for the pps than management wrongs or potential malfeasance. It’s a rough marketplace right not, and thus again patience is needed.
I can’t blame all of it on the new management, AND to boot, the old execs all did get the boot.
So yes it’s rough, but I disagree with the context that all is lost.
First about the shareholder meeting. This is the easy one… I have to point out to be mindful that all the measures put forward will pass. Institutions do own about 80% of the shares still. I understand sending a message, but staying rationale that all measures will pass.
Secondly, there certainly was a debacle w Anil and 5 years of preparing to be unprepared… however, the Rytelo launch is also certainly not all doom and gloom. I will point you to a post on StockTwits this morning about the competitor drug launch Revs… I’ll go and copy/paste it in another thread, but essentially it shows the slow uptake in the first year or so. The previous top Execs certainly messaged poorly, for lack of a curse word, but probably because Dr Scarlett was skilled at drug development but not really experienced with drug commercialization. Now the company has new execs, who are experienced with drug launch commercialization.
So I feel the angst but I don’t feel the storm the Bastille slash potential capitulation vibes … not saying it’s wrong to voice it and have those feelings, I’m just saying I’m not there. Rytelo works and will have uptake, in both the US and soon Europe. Losing patience is justified, but nonetheless patience continues to be warranted.
I’ll also point you to the video of Dr Santini, posted on YouTube yesterday… that was posted on StockTwits (StockTwits coming up money this morning) - longer life expectancy has not been proven out, which is frustrating obviously , and heartbreaking for patients… however Quality of Life is improving , transfusion independence is a real milestone … quick detour to say I wish my dad could have had TI for a short while in the last 3.5 years of his life… and QoL is huge. and the drug is being used in 2nd (by Santini) and ‘mostly 3rd line,,, so there may be potential life expectancy improvement.
Needless to say, this drug therapy is a winner.
I don’t join the line of thought that this is not proving out to be a valuable drug.
Third, and it’s a point of contention and I apologize for being vocal, and inappropriately vocal at times about this, but it’s just a point of fact that there is economic and, in the NIH, political turbulence right now, which as a further point of fact clouds the prospects for new and future drugs. The Biotech indices are down 20% in the past 6 months, and indie / small biotechs have all been pulverized. There has been few mergers / acquisitions of note, which is a marketplace which may have effected the companies plans. But I do think personally that this general market flux is more to blame for the pps than management wrongs or potential malfeasance. It’s a rough marketplace right not, and thus again patience is needed.
I can’t blame all of it on the new management, AND to boot, the old execs all did get the boot.
So yes it’s rough, but I disagree with the context that all is lost.